Ramping up the express stairs: Lisaftoclax in CLL.

Lisaftoclax, a next-generation BCL2 inhibitor, demonstrated promising efficacy and safety in the phase 1b/2 APG2575CU101 trial by Davids et al. in chronic lymphocytic leukemia (CLL).1 With rapid dose ramp-up and high response rates across monotherapy and combination cohorts, including high-risk and previously treated populations, lisaftoclax shows potential as an effective therapeutic option for CLL, pending validation in larger trials.